Difference between revisions of "Gesell"
(Imported from Wikispaces) |
|||
| Line 1: | Line 1: | ||
| + | |||
'''<span style="color: #003366; font-family: arial,helvetica,sans-serif; font-size: 140%;">No evidence for benefit of hyperbaric oxygen therapy in brain radionecrosis (early interim report)</span>''' | '''<span style="color: #003366; font-family: arial,helvetica,sans-serif; font-size: 140%;">No evidence for benefit of hyperbaric oxygen therapy in brain radionecrosis (early interim report)</span>''' | ||
| − | {| | + | |
| − | + | {| style="width: 362px;" | |
|- | |- | ||
| + | | style="width: 352px;" | <span style="font-size:medium;">'''Clinical Bottom Line:'''</span><br/> <span style="font-size:medium;">1. 5 of 7 patients have suffered adverse events</span> | ||
|} | |} | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Citation/s:'''</span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Citation/s:'''</span> <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">Gesell LB, Warnick RE, Brenerman JC, Vogt CJ, Lindsell CJ. A randomized, controlled trial of hyperbaric oxygen therapy for brain radionecrosis. Undersea and Hyperbaric Medicine, 2005. 32(4): 235-236</span> |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">Gesell LB, Warnick RE, Brenerman JC, Vogt CJ, Lindsell CJ. A randomized, controlled trial of hyperbaric oxygen therapy for brain radionecrosis. Undersea and Hyperbaric Medicine, 2005. 32(4): 235-236</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Three-part Clinical Question:''' For patients with brain radionecrosis, does hyperbaric oxygen therapy improve functional outcome?</span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Three-part Clinical Question:''' For patients with brain radionecrosis, does hyperbaric oxygen therapy improve functional outcome?</span> <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Search Terms:''' Radiation injury, Brain tumour, Neuropsychiatric testing</span> |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Search Terms:''' Radiation injury, Brain tumour, Neuropsychiatric testing</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study:'''Non-blinded randomised controlled trial intention-to-treat unknown.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study:'''Non-blinded randomised controlled trial intention-to-treat unknown.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study Patients:''' PET-scan confirmed brain radionecrosis on steroids at a dose that cannot be tapered down</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study Patients:''' PET-scan confirmed brain radionecrosis on steroids at a dose that cannot be tapered down</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Control group''' (N = ?): Steroid treatment, dose adjusted to oedema volume and Karnofsky score, for 3 months</span> | + | |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Experimental group''' (N = ?): As above, plus 60 treatments of 100% oxygen breathing at an unspecified pressure on an ‘accelerated air break’ protocol</span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Control group''' (N = ?): Steroid treatment, dose adjusted to oedema volume and Karnofsky score, for 3 months</span> |
| + | |||
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Experimental group''' (N = ?): As above, plus 60 treatments of 100% oxygen breathing at an unspecified pressure on an ‘accelerated air break’ protocol</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Evidence:'''</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Evidence:'''</span> | ||
| − | {| | + | {| style="width: 486px;" |
| − | |||
|- | |- | ||
| − | | ''' | + | | style="width: 141px;" | <span style="font-size:medium;">'''Outcome'''</span> |
| + | | style="width: 124px; text-align: center;" | <span style="font-size:medium;">'''Time to outcome'''</span> | ||
| + | | style="width: 199px; text-align: center;" | <span style="font-size:medium;"><span style="display: block; font-family: arial, helvetica, sans-serif; text-align: center;">'''Total'''</span></span> | ||
|- | |- | ||
| + | | style="width: 141px;" | <span style="font-size:medium;">'''Adverse events'''</span> | ||
| + | | style="width: 124px; text-align: center;" | <span style="font-size:medium;">unknown</span> | ||
| + | | style="width: 199px; text-align: center;" | <span style="font-size:medium;">5 of 7 patients enrolled</span> | ||
|} | |} | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Comments:'''</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Comments:'''</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Abstract only</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Abstract only</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. 7 patients enrolled, allocation unknown</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. 7 patients enrolled, allocation unknown</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. No discussion of randomization procedure, blinding, or allocation concealment</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. No discussion of randomization procedure, blinding, or allocation concealment</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">4. Severe nature of disease and co-morbidities threaten to disrupt this trial</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">4. Severe nature of disease and co-morbidities threaten to disrupt this trial</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Appraised by:''' A/Prof Mike Bennett, Dr Sean Hopson</span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Appraised by:''' A/Prof Mike Bennett, Dr Sean Hopson</span> <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">Department of Diving and Hyperbaric Medicine Prince of Wales Hospital Sydney ; Friday, 22 September 2006Email: [[mailto:m.bennett@unsw.edu.au| m.bennett@unsw.edu.au]]</span> |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">Department of Diving and Hyperbaric Medicine Prince of Wales Hospital Sydney ; Friday, 22 September 2006Email: [[mailto:m.bennett@unsw.edu.au | m.bennett@unsw.edu.au]]</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Kill or Update By:''' December 2020</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Kill or Update By:''' December 2020</span> | ||
| − | [[File: | + | [[File:Sumhorsa.gif|center|Sumhorsa.gif]] |
| − | <span style="color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;">'''[[ | + | <span style="color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;">'''[[Radiation_tissue_injury|BACK]]'''</span> |
Latest revision as of 01:02, 9 July 2019
No evidence for benefit of hyperbaric oxygen therapy in brain radionecrosis (early interim report)
| Clinical Bottom Line: 1. 5 of 7 patients have suffered adverse events |
Citation/s: Gesell LB, Warnick RE, Brenerman JC, Vogt CJ, Lindsell CJ. A randomized, controlled trial of hyperbaric oxygen therapy for brain radionecrosis. Undersea and Hyperbaric Medicine, 2005. 32(4): 235-236
Three-part Clinical Question: For patients with brain radionecrosis, does hyperbaric oxygen therapy improve functional outcome? Search Terms: Radiation injury, Brain tumour, Neuropsychiatric testing
The Study:Non-blinded randomised controlled trial intention-to-treat unknown.
The Study Patients: PET-scan confirmed brain radionecrosis on steroids at a dose that cannot be tapered down
Control group (N = ?): Steroid treatment, dose adjusted to oedema volume and Karnofsky score, for 3 months
Experimental group (N = ?): As above, plus 60 treatments of 100% oxygen breathing at an unspecified pressure on an ‘accelerated air break’ protocol
The Evidence:
| Outcome | Time to outcome | Total |
| Adverse events | unknown | 5 of 7 patients enrolled |
Comments:
1. Abstract only
2. 7 patients enrolled, allocation unknown
3. No discussion of randomization procedure, blinding, or allocation concealment
4. Severe nature of disease and co-morbidities threaten to disrupt this trial
Appraised by: A/Prof Mike Bennett, Dr Sean Hopson Department of Diving and Hyperbaric Medicine Prince of Wales Hospital Sydney ; Friday, 22 September 2006Email: [m.bennett@unsw.edu.au]
Kill or Update By: December 2020
